HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $9 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on BioCardia (NASDAQ:BCDA) and maintained a $9 price target.
August 10, 2023 | 10:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioCardia's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $9.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for BioCardia. The maintained price target of $9 indicates the firm's continued confidence in the company's potential. This could potentially lead to increased investor confidence and a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100